There are currently 932 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
NCT05634720
Recruiting
This is a window-of-opportunity study which will evaluate the safety and feasibility of single-dose neoadjuvant Hepatic Artery (HA) chemotherapy (FUDR/oxaliplatin) in patients with localized pancreatic ductal adenocarcinoma (PDAC) eligible for surgical resection and systemic chemotherapy. Current standard-of-care therapy for patients with localized PDAC includes surgical resection and six months of systemic chemotherapy. Because the sequence of these treatments (surgery and chemotherapy) is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
Gathering Online for Dialogue and Discussion to Enhance Social Support
NCT05753683
Recruiting
The goal of this trial is to test a modified mobile health intervention (with a group component) relative to a mobile health intervention in a two-arm randomized trial with 500 young African American women who are human immunodeficiency virus (HIV)-negative and who misuse alcohol. The expected outcomes are to: (1) determine the efficacy of the virtual group component in reducing alcohol use and sexual risk and increasing pre-exposure prophylaxis (PrEP) utilization; and (2) understand selected o... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
05/29/2025
Locations: RTI International, Durham, North Carolina
Conditions: Alcohol Misuse, HIV, Sexually Transmitted Infections, Pre-exposure Prophylaxis
Register for Updates
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
NCT06457919
Recruiting
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Duke University, Durham, North Carolina
Conditions: Prostate Cancer
Register for Updates
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844
Recruiting
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Solid Tumor
Register for Updates
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
NCT04545502
Recruiting
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Duke University, Durham, North Carolina
Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Register for Updates
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
NCT04777994
Recruiting
The study will assess the safety, PK, PD, and preliminary efficacy of ABBVCLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBVCLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expans... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Duke Cancer Center /ID# 251975, Durham, North Carolina
Conditions: Advanced Solid Tumor Cancer
Register for Updates
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/28/2025
Locations: Duke University Early Phase Research Unit, Durham, North Carolina
Conditions: Glycogen Storage Disease Type II Infantile Onset
Register for Updates
TReatment for ImmUne Mediated PathopHysiology
NCT04862221
Recruiting
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/28/2025
Locations: Duke University Medical Center - Duke Children's, Durham, North Carolina
Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Register for Updates
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
NCT05889195
Recruiting
It is of current debate whether the use of invasive (referring to a process that requires insertion into the body) standard of care procedures such as a cystoscopy which is a procedure to look inside the bladder using a thin camera called a cystoscope, is appropriate for use in patients with microscopic hematuria or blood in urine invisible to the naked eye. This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low in this population group, approximately 3%. I... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/28/2025
Locations: Durham VA Health Care System, Durham, North Carolina
Conditions: Urothelial Carcinoma
Register for Updates
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377
Recruiting
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/28/2025
Locations: Duke University, Durham, North Carolina
Conditions: Sickle Cell Trait
Register for Updates
Neonatal Platelet Transfusion Threshold Trial
NCT06676904
Recruiting
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Gender:
ALL
Ages:
Between 1 hour and 48 hours
Trial Updated:
05/28/2025
Locations: Duke University, Durham, North Carolina
Conditions: Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Register for Updates